Biomaterial-based strategies for immunomodulation in IBD: current and future scenarios
Instinctive gastrointestinal inflammatory conditions with persistent intestinal inflammation are known as "inflammatory bowel diseases" (IBDs). IBDs are growing progressively common throughout the world although it is still unclear what causes them. IBDs that cause recurrent, intermittent,...
Saved in:
Published in | Journal of materials chemistry. B, Materials for biology and medicine Vol. 11; no. 25; pp. 5668 - 5692 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Royal Society of Chemistry
28.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Instinctive gastrointestinal inflammatory conditions with persistent intestinal inflammation are known as "inflammatory bowel diseases" (IBDs). IBDs are growing progressively common throughout the world although it is still unclear what causes them. IBDs that cause recurrent, intermittent, and disburse inflammatory responses, may also have systemic symptoms such as ulcerative colitis and Crohn's disease. It has been discovered that a number of medications, including antibiotics, corticosteroids, and immune-suppressants, can promote mucous and damaged epithelial restoration. The incidences of general and specific therapy failure in IBD continue to climb, even though the availability of advanced biologics including anti-interleukins, anti-integrins, anti-tumor necrosis factor (anti-TNF), and small molecules such as tofacitinib exist. Management therapies that are currently being researched include specifically JAK (janus kinase) inhibitors, anti-IL (anti-interleukin) (IL-12, IL23), and leukocyte inhibitors such as sphingosine-1-phosphate receptors. Clinical treatments can have various adverse effects. In order to give pharmacological drugs to the disease-specific sites with improved efficacy and fewer complications, innovative frameworks centered on biomaterials are needed. We provide an outlook on the current state of several biomaterials used to treat IBD. This article comprehensively addresses numerous microparticles, nanoparticles, and hydrogels that have recently been made from natural bio-polymers and lipids. To support colon-specific target delivery and steady release of medications during IBD therapies, these various biomaterial-based monotherapies could be employed as efficient drug delivery systems.
Overview of the different nanoformulations in the treatment of IBD. |
---|---|
Bibliography: | Mr Chandrashekhar Jori is a PhD student in the Chemical Biology Unit (CBU), Institute of Nanoscience and Technology (INST) Mohali, India, under the supervision of Dr Rehan Khan. He obtained his master's degree in microbiology from Savitribai Phule Pune University, Pune, India. His research is focused on biomaterials based nanocarriers for the treatment against inflammatory diseases. Dr Rehan Khan has been working as Scientist-D at Institute of Nano Science and Technology (INST), Mohali since 2015. Prior to this, he worked as a post-doctoral fellow at the University of Manitoba, Canada. He obtained his PhD from Jamia Hamdard University, New Delhi. Research in his laboratory at INST, involves the design and development of "Therapeutic nanomicelles or nanoparticles for the treatment of collagen-induced rheumatoid arthritis (RA) and dextran-sodium sulfate (DSS)-induced colitis" in animal models. The research also involves the formulation and characterization of novel nanoparticles for drug delivery purposes for synthetic lethal therapy mediated targeting of colorectal cancer. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 2050-750X 2050-7518 |
DOI: | 10.1039/d3tb00276d |